A bioreactor system for conditioning of pluripotent cells or cell media is provided. In further aspects, conditioned pluripotent cells and methods for making such cells are provided.

The present invention relates to a method of culturing a pancreatic progenitor cell. The method comprises contacting the cell with epidermal growth factor (EGF), retinoic acid (RA) and an inhibitor of transforming growth factor- (TGF-) and 3T3-J2 feeder cells. A cell produced by the method of the invention and a kit when used in the method are also provided.

A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.

Bone marrow containers are described herein. Separation systems for separating activated immune cells from other components are described herein. Methods of activating an immune cell are described herein.

Provided herein are a composition and method for inducing differentiation into myeloid-derived suppressor cells from myeloid cells using glycyrrhizin, and an immunosuppressive composition including the composition or myeloid-derived suppressor cells induced by the method.

Provided herein are also a composition and method for inducing differentiation into CD11b+Gr1 myeloid cells using glycyrrhizin, and a composition for proliferating myeloid cells which includes glycyrrhizin.

Thus, glycyrrhizin of the present disclosure has an effect of inducing differentiation into CD11b+Gr1 myeloid cells or myeloid-derived suppressor cells from myeloid cells in vivo and in vitro, and thus is effective as a composition for inducing differentiation into CD11b+Gr1 myeloid cells or myeloid-derived suppressor cells, which includes the glycyrrhizin.

In addition, when myeloid cells are treated with lipopolysaccharide (LPS) before being treated with the glycyrrhizin of the present disclosure in vitro, the effect of inducing differentiation into CD11b+Gr1 myeloid cells or myeloid-derived suppressor cells from myeloid cells is further enhanced.

The present disclosure provides a method for in vitro activation of immune cells for immune cell therapies. The method includes contacting a population of immune cells with -glucan to obtain a population of conditioned cells. When introduced into a subject, the population of conditioned immune cells inhibits tumor growth in the subject. A method for inhibiting tumor growth using the population of conditioned immune cells is also provided.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45.sup.+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active ingredient as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy, in particular for therapy of cancer.

The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and/or a label as well as methods for producing such isolated cellular targeted delivery system and uses of such system for therapy diagnosis and in particular for diagnosis of cancer, particularly metastatic cancer, in particular for therapy of cancer.

Bone marrow containers are described herein. Separation systems for separating activated immune cells from other components are described herein. Methods of activating an immune cell are described herein.

The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.